Research programme: thyroid hormone receptor agonists - Karo Pharma

Drug Profile

Research programme: thyroid hormone receptor agonists - Karo Pharma

Alternative Names: Research programme: glaucoma therapeutics - Karo Pharma

Latest Information Update: 21 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karo Bio
  • Class
  • Mechanism of Action Thyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glaucoma

Most Recent Events

  • 12 Sep 2006 Discontinued - Preclinical for Glaucoma in Sweden (Ophthalmic)
  • 31 Dec 2001 SIFI have signed a one-year agreement with Karo Bio
  • 07 May 2001 Karo Bio's thyroid hormone receptor agonist eye drops are available for licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top